Table 3.

Inclusion and exclusion criteria for human anti-neutrophil therapy trials, dosage and effect

Phase III trial	Treatment	Inclusion criteria	Exclusion criteria	Dosage	Result
Enlimomab (EAST)	Anti-ICAM-1 antibody	Acute ischemic stroke Enrolment within 6 h of stroke onset No contraindications to treatment	Information not available	First dose within 6 h of stroke onset Repeated doses given every 24 h for a total of 5 Patients assigned a variable fixed-dose regimen	Increased mortality, increased infection compared to placebo
UK-279,276, ASTIN variable dose trial	Neutrophil (CD18, CD11b) inhibitor factor	Acute ischemic stroke Previous independence Age >50 years Presenting with acute stroke within 6 h of onset Baseline Stroke Severity Scale 10–40 Alteplase permitted	Impaired consciousness Premenopause Fixed-eye deviation with hemiplegia Seizure since stroke onset Temperature >38° C Concurrent infection	Single (variable, in ASTIN; fixed, in UK-279,276) dose administered intravenously over a period of 15 min during hospital admission	No treatment effect
Hu23F2G (LeukArrest)	Anti-CD18 antibody	Acute ischemic stroke Enrolment within 10 h of stroke onset Alteplase permitted No contraindications to treatment	Information not available	Single dose within 10 h of stroke onset Second dose 60 h later	No treatment effect Halted early